51st week of 2010 patent applcation highlights part 49 |
Patent application number | Title | Published |
20100323899 | Superconductive element and relative preparation process - A superconductive element is described, comprising a rigid support made of a non-superconductive material, said support comprising at least one superconductive track formed by a groove containing a superconductive material having a density equal to at least 85% of the value of its theoretical density, and the process for producing said element. The present invention also relates to the possible uses of the superconductive elements, and also to superconductive devices comprising said superconductive elements. | 2010-12-23 |
20100323900 | SUPERCONDUCTING COIL APPARATUS - It is desired to perform assemble, disassemble, maintenance and the like, especially of a large site superconducting coil device, in a short time. The superconducting coil device includes a plurality of coil units arranged in a circle circumference to form a toroidal shape. Each of the plurality of coil units includes a cryostat and a superconducting coil stored in the cryostat, and has a first surface parallel with a radius of the circle circumference and a second surface parallel with the radius of the circle circumference and arranged in a first direction side of the circle circumference to the first surface. The first surface contacts with the second surface of a coil unit adjacent in one direction among the plurality of coil units. The second surface contacts with the first surface of a coil unit adjacent in other direction among the plurality of coil units. | 2010-12-23 |
20100323901 | METHOD OF MANUFACTURING SUPERCONDUCTING WIRE - A method of manufacturing a superconducting wire includes the step of drawing a wire formed by coating raw material powder for a superconductor with a metal (S | 2010-12-23 |
20100323902 | Live-cell signals of pathogen intrusion and methods thereof - Disclosed is a system and method for measuring aspects of pathogen intrusion on a live-cell as defined herein. The system and method also provide a method to measure prophylaxis or remedial aspects of a therapeutic candidates in a live-cell or a live-cell model from pathogen intrusion. | 2010-12-23 |
20100323903 | DIAGNOSIS AND PROGNOSIS OF SPECIFIC CANCERS - The present invention provides nucleic acid sequences that are used for identification and diagnosis of specific cancers. The nucleic acid sequences can also be used for prognosis evaluation of a subject based on the expression profile of a biological sample. | 2010-12-23 |
20100323904 | Transcription chip - A transcription chip comprising a substrate and, immobilized thereon, at least one polynucleotide including an element sequence to which a transcription factor can be bound. | 2010-12-23 |
20100323905 | Vhh for the Diagnosis, Prevention and Treatment of Diseases Associated with Protein Aggregates - The present invention provides heavy chain variable domain antibodies (VHH) for preventing and/or dissolving aggregates. VHH of the invention are preferably used in the treatment of human diseases that are associated with the formation of aggregates in the body. The invention further provides, among others, means and methods for selecting and using VHH. | 2010-12-23 |
20100323906 | NANOPLASMONIC MOLECULAR RULER FOR NUCLEASE ACTIVITY AND DNA FOOTPRINTING - This invention provides a nanoplasmonic molecular ruler, which can perform label-free and real-time monitoring of nucleic acid (e.g., DNA) length changes and perform nucleic acid footprinting. In various embodiments the ruler comprises a nucleic acid attached to a nanoparticle, such that changes in the nucleic acid length are detectable using surface plasmon resonance. The nanoplamonic ruler provides a fast and convenient platform for mapping nucleic acid -protein interactions, for nuclease activity monitoring, and for other footprinting related methods. | 2010-12-23 |
20100323907 | FROZEN CELL AND TISSUE MICROARRAYS - The invention is directed to a new composition for making a housing block for cryosectioning comprising agarose and optimal cutting temperature medium. The invention is further directed to new methods for making a frozen section microarray of fresh non-fixed frozen cell or tissue samples that undergo only one freeze-thaw cycle before being used in a biological assay. | 2010-12-23 |
20100323908 | Methods and Compositions For Diagnosing Osteoarthritis In A Feline - Methods, compositions and kits for diagnosing osteoarthritis in a feline are disclosed. The methods of the invention comprise detecting differential expression of at least one biomarker in a body sample. preferably a blood sample, where the biomarker is differentially expressed in osteoarthritis. | 2010-12-23 |
20100323909 | DIAGNOSTIC ASSAY FOR TRYPANOSOMA CRUZI INFECTION - A sensitive, multicomponent diagnostic test for infection with | 2010-12-23 |
20100323910 | DNA Microarray for Quantitative Detection of Microbial Processes in the Oilfield - A DNA microarray having correctly designed target nucleotide sequences bound thereto generates a quantifiable signal when the microarray hybridizes a field sample nucleotide sequence that indicates a microbial process in a field sample from an oilfield, for instance from downhole. Such DNA microarrays may be designed and manufactured to detect microbial production of hydrogen sulfide, organic acids, surfactants, and gases as well as thermophilic bacterial activity. The field sample nucleotide sequences may be tagged with a fluorescent molecular label, so that the DNA microarrays may generate signals, such as fluorescent signals that may be measured and quantified to provide a more accurate way to correlate bacterial processes in the oilfield than presently available methods. | 2010-12-23 |
20100323911 | DETECTION OF WORSENING RENAL DISEASE IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS - Methods for the detection of active lupus nephritis (LN) and worsening renal disease activity and/or active LN in patients diagnosed with systemic lupus erythematosus, using a panel of biomarkers including transferrin (Tf), ceruloplasmin (Cp), alpha-1-acid glycoprotein (AGP1), lipocalin-like prostaglandin D synthetase (L-PGDS), and urinary neutrophil gelatinase associated lipocalin (UNGAL). | 2010-12-23 |
20100323912 | REAL-TIME ANALYTICAL METHODS AND SYSTEMS - The present invention is generally directed to compositions, methods, and systems for performing single-molecule, real-time analysis of a variety of different biological reactions, and for determining various characteristics of the different biological reactions. The ability to analyze such reactions provides an opportunity to study those reactions as well as to potentially identify factors and/or approaches for impacting such reactions, e.g., to stimulate, enhance, or inhibit such reactions. | 2010-12-23 |
20100323913 | Purification and Concentration of Proteins and DNA from a Complex Sample Using Isotachophoresis and a Device to Perform the Purification - A method of simultaneously co-purifying and concentrating nucleic acid and protein targets is described. The method includes automation of the entire sample preparation process, performed by having an analyst add a sample into a device that performs all of the steps necessary to prepare a sample for analysis. The method provides for samples that are not split during the sample preparation process and where common purification methods can be used for purifying multiple analytes. | 2010-12-23 |
20100323914 | Enzymatic Methods for Genotyping on Arrays - Disclosed are methods for enzymatic genotyping of polymorphisms on solid supports. In one aspect the method includes hydrolysis of a nucleotide comprising a label on an array-bound probe by a 5′ to 3′ exonuclease activity specific for single-stranded DNA. If there is target-probe sequence mismatch at the polymorphic position (the labeled nucleotide in the probe), the labeled nucleotide is hydrolyzed from the probe by the exonuclease. The presence of a detectable signal on the array is indicative of the identity of the nucleotide at the polymorphic position in the target. In another aspect, the queried position on the probe may be a labeled ribonucleotide, and if there is a sequence mismatch at the polymorphic position on the probe, the labeled ribonucleotide will be hydrolyzed from the nucleic acid by the activity of an exoribonuclease enzyme specific for single-stranded sequences. | 2010-12-23 |
20100323915 | Porous Substrate Plates And The Use Thereof - A substrate plate or device adapted for use with biological or chemical assays is disclosed. The device may take the form of a multi-well plate having a three-dimensional, porous layer as part of a support surface within each well for immobilizing probe species. The porous layer is characterized as having a plurality of interconnected voids defined by a matrix of contiguous solid material. A method and its variants are also described. | 2010-12-23 |
20100323916 | High-Throughput Biological Screening - In one embodiment, a high-throughput flow system includes an array of wells and a separate mechanical tip positioned within each well. Each mechanical tip is separately actuated to impart a shear stress pattern. | 2010-12-23 |
20100323917 | TAILORED NANOPOST ARRAYS (NAPA) FOR LASER DESORPTION IONIZATION IN MASS SPECTROMETRY - The production and use of semiconducting nanopost arrays made by nanofabrication is described herein. These nanopost arrays (NAPA) provide improved laser ionization yields and controllable fragmentation with switching or modulation capabilities for mass spectrometric detection and identification of samples deposited on them. | 2010-12-23 |
20100323918 | POLYMER SURFACE FUNCTIONALIZATION AND RELATED APPLICATIONS - A method to assemble functional materials, such as nanomaterials, onto a polymer surface to create a corresponding functionalized surface involves creating a solution of the functional material, providing a sacrificial substrate, disposing the functional solution onto a surface of the substrate and then covering the substrate with a liquid polymer. The sacrificial substrate is then dissolved, leaving behind a functional surface embedded within the cured polymer. One specific aspect of the invention relates to the embedding of functionalized carbon nanotubes onto a polymer surface for creating a nano-engineered surface. Devices employing functional surfaces are disclosed that are suitable for the immobilization of enzymes, DNA, peptides, proteins, cells, catalyst, and/or other chemicals or molecules for chemical, biochemical, or biological analysis, reactions, filtration. | 2010-12-23 |
20100323919 | SAMPLE MULTIPROCESSING - A sample processing vessel may include a branch segment and at least two tracks. The at least two tracks may be fluidly isolated from one another by a permanent seal. The tracks may be segmented by breakable seals. The branch segment may be temporarily isolated from the tracks by breakable seal(s) and put in fluid communication with the tracks once those seal(s) are broken, such that fluid received by the branch segment is divided into portions that pass into both tracks. | 2010-12-23 |
20100323920 | ALLOGENEIC STEM CELL BANK - This invention provides methods for supplying a therapy for individuals exposed to radiation following a nuclear event, through the prospective establishment of an undesignated allogeneic stem cell bank with prospective HLA typing of healthy potential recipients. | 2010-12-23 |
20100323921 | MOLECULAR PROGNOSTIC SIGNATURE FOR PREDICTING BREAST CANCER METASTASIS, AND USES THEREOF - The present invention is based on the discovery of a unique 14-gene molecular prognostic signature that is useful for predicting breast cancer metastasis. In particular, the present invention relates to methods and reagents for detecting and profiling the expression levels of these genes, and methods of using the expression level information in predicting risk of breast cancer metastasis. | 2010-12-23 |
20100323922 | siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TAF1 | 2010-12-23 |
20100323923 | Thermal Cycling Device - Apparatus for controlling the temperature of a reaction mixture held within a reaction container, the apparatus including a radiation source for exposing the reaction container to radiation thereby heating the reaction mixture, a temperature sensor for sensing a temperature indicative of a reaction mixture temperature and a controller for controlling the radiation source in accordance with the reaction mixture temperature to thereby selectively heat the reaction mixture. | 2010-12-23 |
20100323924 | METHOD OF MANUFACTURING MICRO PATTERNED DEVICE AND DEVICE OBTAINED BY THE METHOD - The present invention refers to a method of manufacturing a micro patterned device. The method can comprise or consist of applying a light curable epoxy resin to a mold to obtain a curable resin filled mold. In a further step a polymeric film or an epoxy resin-coated glass is applied over the curable resin filled mold. Subsequently, the curable resin filled mold to which the polymeric film or the epoxy resin-coated glass is applied is irradiated to cure the resin. In another aspect the present invention refers to a micro patterned device obtained by a method described herein. | 2010-12-23 |
20100323925 | Nanosensor array for electronic olfaction - A detector system is described including arrays having a plurality of nanoelectronic sensors comprising a channel including a nanostructured element disposed on a substrate, the nanostructured element functionalized by one or more materials disposed on or adjacent to the nanostructured element so as to operatively influence one or more sensor electrical properties. In certain embodiments, the nanostructured element comprise one or more nanotubes, and the functionalization material may include nanoparticles composed of one or more metals, metal oxides, salts, or other inorganic or organic materials or composites of these. | 2010-12-23 |
20100323926 | DIAGNOSIS DEVICE AND METHOD OF MANUFACTURING THE DIAGNOSIS DEVICE - Provided are a diagnosis device in which a bio-chemical reaction between a reference sample and a target sample occurs and a result of the bio-chemical reaction can be detected and a method of manufacturing the diagnosis device. The diagnosis device includes an image sensor where a plurality of photo-detectors are formed; a polymer layer which is made of a polymer material and formed on an upper portion of the image sensor; and a plurality of wells which are formed corresponding to the plurality of photo-detectors on the polymer layer, wherein an inner portion of each well is empty. | 2010-12-23 |
20100323927 | EQUIVALENT CIRCULATING DENSITY CONTROL IN DEEP WATER DRILLING - A method of providing a substantially constant rheological profile of a drilling fluid over a temperature range of about 120° F. to about 40° F. includes adding a drilling fluid additive to the drilling fluid, wherein the drilling fluid additive includes the reaction product of a carboxylic acid with at least two carboxylic moieties; and a polyamine having an amine functionality of two or more. A composition, such as an oil based drilling fluid, includes the reaction product of a carboxylic acid with at least two carboxylic moieties and a polyamine having an amine functionality of two or more. | 2010-12-23 |
20100323928 | Method of creating a carbon dioxide hydrate - A method of creating a carbon dioxide hydrate is disclosed. The preferred steps include supplying liquid carbon dioxide and a dissociation agent to a hydrocarbon hydrate, decomposing the hydrocarbon hydrate by the dissociation agent into a hydrocarbon gas and liquid water, and forming the carbon dioxide hydrate from the liquid carbon dioxide and the liquid water. The dissociation agent preferably is at least one of an inorganic salt, a surface active agent, a hydrate inhibitor, and an absorption solution. Furthermore, a substance composition of liquid carbon dioxide and the dissociation agent is described, which is provided for depositing carbon dioxide hydrate in a subterranean geological formation. Furthermore, a deposition device is described, which is configured for depositing carbon dioxide hydrate in a subterranean geological formation. | 2010-12-23 |
20100323929 | Methods for Treating a Well with a Cross-Linked Water-Soluble Polymer-Complexed Metal Cation Network and an Aromatic Compound Capable of Forming a Chelating Agent to Uncross-Link the Polymer - Methods are provided for treating a portion of a well. The method according to this aspect comprises the steps of: (A) forming a treatment fluid, the treatment fluid comprising: (i) water; (ii) a water-soluble polymer; (iii) a complexed metal cation that: (a) has a valence state of at least three; and (b) is capable of cross-linking the water-soluble polymer; and (iv) an aromatic compound that is capable of dissolving, melting, or chemically decomposing, dissociating, or reacting, to form a chelating agent, wherein the chelating agent comprising vicinal substituents containing donor heteroatoms, and wherein the chelating agent is capable of chelating the metal cation; and (B) introducing the treatment fluid into the well. | 2010-12-23 |
20100323930 | METHOD FOR PRODUCING SOLID MATERIALS ON THE BASIS OF SYNTHETIC POLYMERS AND/OR BIOPOLYMERS AND USE THEREOF - The use of solid materials based on synthetic polymers and/or biopolymers (A) in natural gas and mineral oil extraction technology. The solid materials are produced by solubilizing at least one synthetic polymer and/or biopolymer (A), or at least one synthetic polymer and/or biopolymer (A) and at least one additive (B), in at least one substantially anhydrous chaotropic liquid (C). The solution or dispersion (AC) or (ABC) is contacted with a liquid (D1) which is miscible with the chaotropic liquid (C), but in which at least the synthetic polymer and/or the biopolymer (A) are substantially insoluble, resulting in a phase (E). The chaotropic liquid (C) is removed from phase (E) to result in a gel (G), which is impregnated with a liquid (D2). The two liquids (D1) and (D2) are removed from the gel (G) by evaporating, producing a solid material based on synthetic polymer and/or biopolymer (A). | 2010-12-23 |
20100323931 | STABILISED EMULSIONS - A method and system are described in which a first composition may be delivered to a target location, which target location may include but is not limited to a location in a wellbore penetrating an earth formation. The first composition is dispersed into a second composition to form an emulsion, where the emulsion is stabilized by particles that are responsive to a magnetic field. The emulsion is used to transport the first composition to the target location where the emulsion is subjected to a magnetic field sufficient to interact with the particles and disrupt the emulsion, and thereby change the viscosity of the composition and/or release the first composition at the target location. In some aspects, the first and second composition may react together upon the release of the first composition at the target location. | 2010-12-23 |
20100323932 | METHODS FOR TREATING A WELL OR THE LIKE - A method is disclosed where introducing into a wellbore a degradable material stabilized in a non-aqueous based fluid. | 2010-12-23 |
20100323933 | Hydrocarbon-Based Filtercake Dissolution Fluid - Embodiments of this invention relate to a composition and a method for dissolving a filtercake in a subterranean formation comprising forming a mixture comprising a dissolution fluid and a fluid comprising hydrocarbon; introducing the mixture into a subterranean formation containing a filtercake; introducing an aqueous fluid to the mixture; and dissolving the filtercake. Embodiments of this invention also relate to further exposing the mixture to swellable packer. Embodiments of this invention relate to a method for a composition, comprising a fluid comprising hydrocarbon; and a dissolution fluid, wherein the fluid comprising hydrocarbon and dissolution fluid are combined to form a miscible mixture that dissolves a filtercake in a subterranean formation. | 2010-12-23 |
20100323934 | GREASE COMPOSITION FOR CONSTANT VELOCITY JOINT AND CONSTANT VELOCITY JOINT - A grease composition which provides, in the working range of 150° C. to −40° C., an enhanced temperature control performance, a reduced low-temperature rotational torque and an improved boot resistance; and a constant velocity joint wherein the grease composition is filled; are provided. A grease composition for a constant velocity joint comprising the following components (A) to (E):
| 2010-12-23 |
20100323935 | Lubricating Composition Containing Borated Phospholipid - The invention relates to a lubricating composition containing (a) a borated phospholipid, (b) an amine salt of a phosphoric acid ester, and (c) an oil of lubricating viscosity. The invention further provides for the use of the lubricating composition for lubricating a limited slip differential. | 2010-12-23 |
20100323936 | LUBRICANT BASE OILS AND LUBRICANT COMPOSITIONS AND METHOD FOR MAKING THEM - A liquid lubricant base oil composition comprising (i) a base stock comprising at least 95% by weight saturated hydrocarbons such as for example a Group II base stock, a Group III base stock and/or a base stock derived from Fischer-Tropsch synthesised, waxy, paraffinic hydrocarbon material and (ii) 0.2 to 30% by weight of an aromatic extract which has a dimethyl sulphoxide extractable polycyclic aromatics content of less than 3 weight % may be made by blending the components together and may be used with one or more additives in a lubricant composition which may be used in applications such as marine engine lubricants. | 2010-12-23 |
20100323937 | Base stocks and lubricant blends containing poly-alpha olefins - This disclosure relates to substantially atactic polymers of at least one of propylene, 1-butene or 1-pentene, processes for making such polymers and compositions including the polymers. The polymers may be used as lubricants or may be combined with low viscosity base stocks to form lubricants. The polymers may be made in the presence of a metallocene catalyst with a non-coordinating anion activator and optionally with hydrogen. | 2010-12-23 |
20100323938 | Product - Aminoplast microcapsules comprising a core of fragrance and a shell of aminoplast polymer, the composition of the shell being from 75-100% of a thermoset resin comprising 50-90% of a terpolymer and from 10-50% of a polymeric stabilizer; the terpolymer comprising:
| 2010-12-23 |
20100323939 | ALCOHOL-BASED SKIN CLEANSER - The invention provides a composition for cleansing skin comprising an emulsifiable organic solvent, such as ethanol or isopropyl alcohol, water, sodium benzoate, and a natural essential oil comprising a complex solution of compounds derived from a plant having topical antimicrobial activity. Natural essential oils useful as antimicrobials include tea tree, oregano, patchouli, rosemary, lemongrass, rose geranium, wild lavender, clove, lemon, | 2010-12-23 |
20100323940 | ALKALINE DETERGENT CONTAINING MIXING ORGANIC AND INORGANIC SEQUESTRANTS RESULTING IN IMPROVED SOIL REMOVAL - Solid block alkaline detergent compositions are disclosed comprising a source of alkalinity, and other detergent additives including sequestrants. The solid block detergents of the invention used a mixed inorganic and organic sequestrant composition that successfully softens service water used in manufacturing aqueous detergents from the composition, but also obtains substantially improved organic soil removal on dishware or flatware. The solid block detergents of the invention comprise large masses of the chemical ingredients having a weight of greater than about 500 grams in a solid block product format that is typically dispensed using a spray on water dispenser that creates an aqueous concentrate that is used in a washing machine. | 2010-12-23 |
20100323941 | Automatic Dishwashing Detergent - An automatic dishwashing detergent, comprising, by weight: 2-10% sodium citrate dehydrate; 0.5 to 2.0% citric acid; 0.5 to 10.0% of a first surfactant, 0.8 to 1.1% xanthan gum; 0.1 to 5.0% of an enzyme; 0.5 to 10.0% of a second surfactant; and the balance being water. The dishwashing detergent can optionally include a preservative and/or an essential oil. | 2010-12-23 |
20100323942 | Liquid Hand Dishwashing Detergent Composition - A hand dishwashing detergent composition comprising a chelant and branched surfactants to provide superior grease cleaning and shine. | 2010-12-23 |
20100323943 | Liquid Hand Dishwashing Detergent Composition - A hand dishwashing detergent composition comprising a chelant and a specific surfactant system to provide superior grease cleaning and shine. | 2010-12-23 |
20100323944 | CLEANING AGENT - A cleaning agent made of a mixture of a first solution and a second solution wherein the first solution is a mixture of water and sodium bicarbonate which has been passed through a positively charged magnetic field and wherein the second solution is a mixture of water and sodium silicate which has been passed through a negatively charged magnetic field. | 2010-12-23 |
20100323945 | Particles Comprising Active Compounds - The present invention relates to a particle comprising an enzyme and a polymer wherein the enzyme and polymer are present as a mixture in the particle and the polymer is substantially soluble in an aqueous solution having an ionic strength of 0 mol/kg and insoluble in an aqueous solution having an ionic strength of more than 1 mol/kg according to method 1 of the invention. The invention also relates to a process for the preparation of the particles, to a composition comprising the particles and to the use of the composition for cleaning clothes. | 2010-12-23 |
20100323946 | Liquid Cleaning Compositions and Methods of Use and Manaufacture - This invention encompasses a light duty liquid detergent composition that includes a C | 2010-12-23 |
20100323947 | Portable Cleaning Article and the Forming method thereof - A portable cleaning article includes a coated capsule and cleaning agent, in which the cleaning agent is contained within the coated capsule, the characteristic in that: the coated capsule having a thin-film layer and an oil layer that is coated over the surface of the thin-film layer to form a portable cleaning article. When the coated capsule is brought into contact with water by the user, the coated capsule dissolves in water for the cleaning agent to exert its cleaning function. | 2010-12-23 |
20100323948 | USE OF SELECTED SURFACTANTS IN CLEANSING COMPOSITIONS - The invention relates to selected surface-active substances of groups a) and b), the surface-active compound a) being selected from compounds of general formula (Ia), wherein M represents a group CH | 2010-12-23 |
20100323949 | ERYTHROPOIETIN MIMETIC PEPTIDE DERIVATIVE AND ITS PHARMACEUTICAL SALTS, THE PREPARATION AND USES THEREOF - What is provided is EPO mimetic peptide derivatives defined as formula (I) and their pharmaceutical salts, the preparation thereof, wherein R | 2010-12-23 |
20100323950 | USE OF BETA-MELANOTROPIN AS A THERAPEUTIC AGENT, EG FOR THE TREATMENT OF AIDS OR ALZHEIMER - The present invention is directed to the use of the peptide compound Ala-Glu-Lys-Lys-Asp-Glu-Gly-Pro-Tyr-Arg-Met-Glu-His-Phe-Arg-Trp-Gly-Ser-Pro-Pro-Lys-Asp-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ala-Glu-Lys-Lys-Asp-Glu-Gly-Pro-Tyr-Arg-Met-Glu-His-Phe-Arg-Trp-Gly-Ser-Pro-Pro-Lys-Asp-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-12-23 |
20100323951 | ANTIBACTERIAL PEPTIDES ACTIVE IN SYSTEMIC INFECTIONS - Antimicrobial peptides of the formula are provided: X | 2010-12-23 |
20100323952 | Nucleoside Analogs in Combination Therapy of Herpes Simplex Infections - A pharmaceutical product comprising a nucleoside analogue active against herpes simplex virus, such as acyclovir/valaciclovir or peniclovir/famciclovir, and an immunosuppressant, as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention of herpes simplex virus infections. | 2010-12-23 |
20100323953 | MACROCYCLIC HEPATITIS C PROTEASE INHIBITORS - The present invention provides novel macrocyclic compounds that mimic peptide substrates of the hepatitis C viral protease and inhibit the viral protease, more particularly as inhibitors of the NS3 serine protease from hepatitis C virus. Methods for synthesis of the compounds are also provided. The compounds find utility as antiviral agents directed at hepatitis C. The invention further provides methods of employing such inhibitors, alone or in combination with other therapeutic agents, to treat hepatitis C infection in a subject in need of such treatment. | 2010-12-23 |
20100323954 | CHIMERIC POLYPEPTIDES AND USES THEREOF - The disclosure provides nucleic acid molecules encoding chimeric polypeptides, chimeric polypeptides, pharmaceutical compositions comprising chimeric polypeptides, and methods for treating metabolic disorders such as diabetes and obesity using such nucleic acids, polypeptides, or pharmaceutical compositions. | 2010-12-23 |
20100323955 | METHODS FOR TREATING OBESITY AND OBESITY RELATED DISEASES AND DISORDERS - Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain. | 2010-12-23 |
20100323956 | GLUCOSE-REGULATING POLYPEPTIDES AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising glucose regulating peptides linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of glucose regulating peptide-related diseases, disorders, and conditions. | 2010-12-23 |
20100323957 | NOVEL ASSAY FOR INHIBITORS OF EGFR - The invention provides methods and compositions for screening for modulators of EGFR activity. In particular, an assay for such modulators is provided, which includes methods of screening for modulators using models of the three dimensional structure of EGFR kinase domains. | 2010-12-23 |
20100323958 | Methods of Use of Biomaterial and Injectable Implant Containing Biomaterial - This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for use in the invention may comprise an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to the use of a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. The invention also includes the use of various medicaments in the biomaterial formulations to enhance the treatment of the affected area of the body. | 2010-12-23 |
20100323959 | Methods of Use of Biomaterial and Injectable Implant Containing Biomaterial - This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for use in the invention may comprise an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to the use of a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. The invention also includes the use of various medicaments in the biomaterial formulations to enhance the treatment of the affected area of the body. | 2010-12-23 |
20100323960 | Methods of Use of Biomaterial and Injectable Implant Containing Biomaterial - This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for use in the invention may comprise an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to the use of a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. The invention also includes the use of various medicaments in the biomaterial formulations to enhance the treatment of the affected area of the body. | 2010-12-23 |
20100323961 | SURFACE ERODING SUTURES - Barbed surgical sutures comprised of surface eroding materials are provided having increased degradation rates are provided. | 2010-12-23 |
20100323962 | Method of Reduction of Wrinkles on Skin, Darkening of Hair and Acceleration of Wound Healing by Applying Peptides Related to Basic Fibroblast Growth Factor (bFGF) - The present invention is directed to synergistic therapies for the treatment of vitiligo. Particularly, the invention is directed to a composition for the reduction of wrinkles on skin, the acceleration of wound healing, and the darkening of hair including a peptide and an acceptable carrier. The peptide may be selected from the group consisting of the peptide of SEQ. ID | 2010-12-23 |
20100323963 | CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF - The present invention provides conjugates of disorazoles and their derivatives with cell-binding molecules, such as peptides, proteins, hormones, blood proteins and antibodies. The present invention further provides novel disorazole derivatives and processes of manufacturing such conjugates and disorazole derivatives. These compounds can be used as medicaments for the treatment of physiological and/or pathophysiological conditions in mammals, in particular for the treatment of various tumors. | 2010-12-23 |
20100323964 | NEW NON-SELECTIVE SOMATOSTATIN ANALOGUES - The present invention relates to a new class of cyclopeptides of formula ( | 2010-12-23 |
20100323965 | Thrombopoietin Mimetics - The invention relates to compounds and their use in the treatment of thrombocytopenia resulting from diseases or conditions such as immune thrombocytopenic purpura, cancer chemotherapy, surgery, bone marrow or stem cell transplantation, radiation injury or treatment, chronic viral infection, and pancytopenia. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods for treating such diseases or conditions in a mammal, including a human, by administering to such mammal an effective amount of a selected thrombopoietin receptor agonist. | 2010-12-23 |
20100323966 | FVIII Peptides and Their Use in Tolerising Haemophiliacs - The present invention provides a peptide comprising a core residue sequence derivable from human FVIII which peptide is capable of binding to an MHC class II molecule without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of inhibitor antibody formation in haemophilia A and/or acquired haemophilia. | 2010-12-23 |
20100323967 | RNA Antagonist Compounds for the Modulation of MCL-1 - Oligonucleotides directed against the Mcl-1 gene are developed for modulating the expression of Mcl-1 protein. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding Mcl-1. Methods of using these compounds for modulation of Mcl-1 expression and for the treatment of diseases associated with over expression of Mcl-1 are provided. Examples of such diseases include cancer and systemic mastocytosis. | 2010-12-23 |
20100323968 | Process of inhibiting cell death in injured cartilage - Processes for inhibiting apoptotic cell death and glycosaminoglycan release from injured cartilage is provided. Inhibition is accomplished using caspase inhibitors. | 2010-12-23 |
20100323969 | Compounds Binding to P-Selectin - The present invention relates to derivatives of compounds which bind selectively to the adhesion molecule human P-selectin, and particularly to such derivatives which comprise a peptide moiety or a functional equivalent of said peptide moiety and are represented by X(A | 2010-12-23 |
20100323970 | SAP VARIANTS AND THEIR USE - Polypeptides are susceptible to denaturation or enzymatic degradation in the blood, liver or kidney. Due to the low stability of some polypeptides, it has been required to administer polypeptide drugs in a sustained frequency to a subject in order to maintain an effective plasma concentration of the active substance. Furthermore, pharmaceutical compositions of therapeutic peptides preferably have a shelf-life of several years in order to be suitable for common use. However, peptide compositions are inherently unstable due to sensitivity towards chemical and physical degradation. In part, the invention provides SAP variant proteins, compositions, pharmaceutical preparations and formulations having a prolonged in vivo half-life, prolonged shelf-life, or rather increased in vitro stability, or increased manufacturing efficiency compared to human SAP. Advantages of increased plasma half-life include, but are not limited to, reducing the amount and/or frequency of dosing. | 2010-12-23 |
20100323971 | CELL PERMEABLE NM23 RECOMBINANT PROTEINS, POLYNUCLEOTIDES ENCODING THE SAME, AND ANTI-METASTATIC COMPOSITION COMPRISING THE SAME - The present invention discloses cell permeable Nm23 recombinant proteins where a macromolecule transduction domain (MTD) is fused to a metastasis suppressor Nm23. Also disclosed are polynucleotides encoding the cell permeable Nm23 recombinant proteins, an expression vector containing the cell permeable Nm23 recombinant protein, and a pharmaceutical composition for preventing metastasis which contains the cell permeable Nm23 recombinant protein as an effective ingredient. The cell permeable Nm23 recombinant proteins of the present invention can induce KSR phosphorylation and inactivation and inhibit Ras-mediated MAPK cascade by efficiently introducing a metastasis suppressor Nm23 into a cell. Therefore, the cell permeable Nm23 recombinant proteins of the present invention can be effectively used as an anti-metastatic agent capable of preventing cancer metastasis by inhibiting the proliferation, differentiation and migration of cancer cells. | 2010-12-23 |
20100323972 | NON-IMMUNOSUPPRESSIVE CYCLOSPORIN FOR THE TREATMENT OF MUSCULAR DYSTROPHY - The present invention relates to the use of a non-immunosuppressive cyclosporin A derivative for preventing or reducing muscular degeneration in a subject suffering from Limb-Girdle muscular Dystrophy. | 2010-12-23 |
20100323973 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS - Described herein are compositions and methods for use in targeted drug delivery using cell receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in imaging, diagnosing, and/or treating diseases and disease states caused by pathogenic cell populations. | 2010-12-23 |
20100323974 | Inhibitors of PARP Activity and Uses Thereof - The present invention relates to new inhibitors of the nucleic enzyme poly(adenosine 5′-diphospho-ribose) polymerase [“poly(ADP-ribose) polymerase” or “PARP”, which is also sometimes called “PARS” for poly(ADP-ribose) synthetase]. More particularly, the invention relates to the use of PARP inhibitors to prevent and/or treat tissue damage resulting from cell damage or death due to necrosis or apoptosis; neural tissue damage resulting from ischemia and reperfusion injury; neurological disorders and neurodegenerative diseases; to prevent or treat vascular stroke; to treat or prevent cardiovascular disorders; to treat other conditions and/or disorders such as age-related macular degeneration, AIDS and other immune senescence diseases, arthritis, atherosclerosis, cachexia, cancer, degenerative diseases of skeletal muscle involving replicative senescence, diabetes, head trauma, immune senescence, inflammatory bowel disorders (such as colitis and Crohn's disease), muscular dystrophy, osteoarthritis, osteoporosis, chronic and acute pain (such as neuropathic pain), renal failure, retinal ischemia, septic shock (such as endotoxic shock), and skin aging; to extend the lifespan and proliferative capacity of cells; to alter gene expression of senescent cells; or to radiosensitize hypoxic tumor cells. | 2010-12-23 |
20100323975 | THERAPEUTIC AGENT FOR CEREBRAL ISCHEMIC INJURY - A therapeutic agent for cerebral ischemic injury contains at least one selected from L-alanyl-L-histidine and glycyl-L-histidine as an active ingredient. The therapeutic agent for cerebral ischemic injury preferably has a dosage form as an injection for intravenous administration. The therapeutic agent for cerebral ischemic injury having a dosage form as an aqueous injection contains at least one selected from L-alanyl-L-histidine and glycyl-L-histidine at a concentration of preferably 0.3 to 3.5 mol/L, and more preferably 0.6 to 2.1 mol/L. | 2010-12-23 |
20100323976 | NOVEL ANTI-INFLAMMATORY PRO-DRUGS - The present invention relates to compounds according to formula (I): wherein R | 2010-12-23 |
20100323977 | Mucoadhesive nanoparticles for cancer treatment - The present invention relates to a pharmaceutical composition which includes nanoparticles. The nanoparticles include a glyceryl monooleate or monolinoleate (or other mono fatty acid ester); a chitosan; and a cancer therapeutic agent, such as gemcitabine, taxanes, and hydrophobic cancer therapeutic agents). Also disclosed are methods for preparing such nanoparticles and pharmaceutical compositions, as well as methods for treating breast, pancreatic, colon, prostate, and other cancers by parenterally, intravenously, or otherwise administering such nanoparticles and pharmaceutical compositions. | 2010-12-23 |
20100323978 | Non-aqueous oil delivery system for ophthalmic drugs - The present invention relates to a delivery system for ophthalmic drugs, and more particularly, to a non aqueous oil delivery system. Low concentrations of ophthalmic drugs suspended in an oil vehicle delivery system are as therapeutically effective in man and animals as the corresponding higher concentrations of ophthalmic drugs that are commercially used in aqueous solutions. Eye drops that utilize this nonaqueous oil delivery system, when used in man, are comfortable to use and produce little ocular irritation, have a longer shelf-life, low systemic toxic potential, and only short term blurring of vision. Using this nonaqueous oil delivery system, a single drop of ophthalmic drug with a concentration that is 10 times less than the same drug used in commercially available aqueous eye drops is as effective as the commercially available aqueous ophthalmic eye drops that require many applications to be effective. In addition, utilizing the nonaqueous oil delivery system as eye drops produces no ocular sensation of burning, stinging or excessive tearing that is commonly associated with the commercially available aqueous eye drops. This very dilute ophthalmic drug preparation has a greatly reduced systemic toxicity potential as compared to the commercially used aqueous ophthalmic drops. The vehicle includes castor oil, corn oil, glycerol, mineral oil USP, vegetable oil, white petrolatum USP, and mixtures, there of. The ophthalmic class of drugs includes antimicrobials, miotics, mydriatics, mydriatic-cycloplegics, mydriatic-cycloplegic reversal agents and topical anesthetics. | 2010-12-23 |
20100323979 | METHODS AND COMPOSITIONS FOR INHIBITING PROLIFERATION OF ANEUPLOID CELLS - The present invention relates, in part, to the use of AMP kinase agonists to reduce or inhibit the proliferation of aneuploid cells. The invention is also directed to the use AMP kinase agonists to reduce or inhibit the proliferation of solid tumors characterized by aneuploidy in an individual. | 2010-12-23 |
20100323980 | Improvements to analogous compounds of 6-thioguanosine triphosphate, their use in medical fields and processes for their preparation - The invention relates to analogous compounds of 6-thioguanosine triphosphate of general formula (I). A compound of the general formula (I); wherein the dashed bond in the sugar moiety can be either single or double and wherein R1, R2, R3, R4 or R5, equal or different between each other, have general formula -(Int) | 2010-12-23 |
20100323981 | TREATMENT OF STATIN SIDE EFFECTS - The present invention relates generally to treatment of muscle pain and/or fatigue and to methods for treatment of side effects of statin therapy. In particular, the invention relates to the use of certain substituted benzoquinones, e.g. Coenzymes Q, particularly Coenzyme Q10 (Q10), in therapy. The invention also relates to the use of Q10 in combinative therapy with other agents such as uridine, its biological precursors or salts, esters, tautomers or analogues thereof (“uridine related compounds”). The invention is also directed to compositions, uses and combination packs or kits related to the treatment methods. | 2010-12-23 |
20100323982 | FOOD COMPOSITION FOR PRODROMAL DEMENTIA PATIENTS - A composition comprising (a) one or more ω-3 fatty acids selected from DHA, DPA and EPA, (b) uridine or its equivalent, and (c) a methyl donor, useful in the treatment of a person having characteristics of a prodromal dementia patient. The characteristics include e.g. a level of more than 350 ng Total-tau per litre cerebrospinal fluid (CSF), and a weight ratio of abeta-42/Phospho-tau-181 of less than 6.5 in CSF. | 2010-12-23 |
20100323983 | PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND/OR PARENTERAL APPLICATION, PREPARATION METHODS THEREOF, AND USES THEREOF - The invention relates to the combination of hyaluronic acid and of at least one hyaluronic acid oligomer constituted of 1 to 2 disaccharide units. The invention is of use in particular in human dermatology or in reconstructive surgery. | 2010-12-23 |
20100323984 | COSMETIC ORAL AND/OR PARENTERAL USE OF GLUCOSAMINE OPTIONALLY IN COMBINATION WITH AT LEAST ONE POLYPHENOL COMPOUND, AND CORRESPONDING COMPOSITION - The present invention relates to the cosmetic oral and/or parenteral use of glucosamine as an active agent for preventing and/or treating the cutaneous signs of ageing, optionally in combination with at least one polyphenol compound. | 2010-12-23 |
20100323985 | PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND/OR PARENTERAL APPLICATION, PREPARATION METHODS THEREOF AND USE OF SAME - The invention relates to a combination of hyaluronic acid and of at least one inhibitor of hyaluronic acid degradation, for use in particular in human dermatology or in reconstructive surgery. | 2010-12-23 |
20100323986 | COMPOSITIONS AND METHODS FOR MODULATION OF VASCULAR STRUCTURE AND/OR FUNCTION - The present invention relates to compositions comprising semi-crystalline β-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other organic and inorganic contaminants, and whose constituent monosaccharide sugars are attached in a β-1-4 conformation. | 2010-12-23 |
20100323987 | COMBINATIONS OF RETIGABINE AND SODIUM CHANNEL INHIBITORS OR SODIUM CHANNEL-INFLUENCING ACTIVE COMPOUNDS FOR TREATING PAINS - The invention relates to pharmaceutical combinations of retigabine and sodium channel inhibitors for treating, pains which are accompanied by an increase in muscle tone. | 2010-12-23 |
20100323988 | SOLID CITRATE AND TARTRATE SALTS OF DPP-IV INHIBITORS - This invention relates to DPP-IV inhibitory citrate or tartrate salts of pyrrolidinylaminoacetyl pyrrolid acid compounds that are physically and chemically stable, substantially non-deliquescent solids under ambient conditions. | 2010-12-23 |
20100323989 | PHARMACEUTICAL COMBINATIONS USEFUL FOR TREATING HCV - This invention relates to combinations of Compound 1 and Compound 2 which are useful for treating hepatitis C virus infection. | 2010-12-23 |
20100323990 | SHIP 1 MODULATOR PRODRUGS - The present invention provides the use of prodrugs of pelorol and homopelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP1 activity. A compound or a pharmaceutical composition of the present invention may be used for the treatment or prophylaxis of an inflammatory, neoplastic, hematopoetic or immune disorder or condition in addition to other disorders and conditions. | 2010-12-23 |
20100323991 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES - The invention provides a method of treating a disease or condition mediated by vascular hyperpermeability in an animal. The method comprises administering an amount of a danazol compound effective to inhibit vascular hyperpermeability and an amount of a second drug effective to treat the disease or condition. The invention further provides a method of inhibiting vascular hyperpermeability when it is a side effect caused by administration of a drug to, or another treatment of, an animal. The method comprises administration of an amount of a danazol compound effective to inhibit the vascular hyperpermeability. The invention also provides a method of modulating the cytoskeleton of endothelial cells in an animal comprising administering an amount of a danazol compound and an amount of a second drug effective to modulate the cytoskeleton. The present invention also relates to pharmaceutical compositions and kits comprising a danazol compound and a second drug. | 2010-12-23 |
20100323992 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING AND TREATING EYE PATHOLOGIES - The present invention relates to pharmacology, medicine, opthalmology, and, in particular, concerns a class of chemical compounds of structure (I) and also their solvates, isomers or prodrugs applicable when incorporated into pharmaceutical compositions also containing pharmaceutically acceptable carrier which can be useful for prophylaxis and treatment of different eye pathologies such as cataract and macular dystrophy. | 2010-12-23 |
20100323993 | USES OF PENTAMIDINE AND RELATED COMPOUNDS - Methods are provided herein for treatment of myotonic dystrophy and other toxic RNA diseases in a subject. In some examples, the method comprises administration of a compound that binds a nucleotide repeat expansion in a ribonucleic acid molecule, thereby treating the disease. In additional examples, the method comprises administration of a compound that disrupts binding of muscleblind-like proteins to an RNA nucleotide repeat expansion. Compounds for use in the disclosed method include pentamidine or heptamidine or derivatives thereof. Representative compounds are described herein. | 2010-12-23 |
20100323994 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS - The invention provides compounds of formula I | 2010-12-23 |
20100323995 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING NEURODEGENERATION IN ACUTE AND CHRONIC INJURIES IN THE CENTRAL NERVOUS SYSTEM - The present invention provides compositions and methods for prevention and prophylaxis of neurological diseases accompanied by neuronal death. The invention includes synthesis of 5-benzylamino salicylic acid (BAS) and its derivatives. BAS and its derivatives protect cortical neurons from toxic insults by N-methyl-D-aspartate, Zn | 2010-12-23 |
20100323996 | MEANS AND METHODS OF CONTROLLING COMMENSALES - The present invention relates to a cosmetic composition for the cleaning of the skin, said composition comprising or consisting of one or more compounds of formula (I) | 2010-12-23 |
20100323997 | NOVEL USES - The present invention relates to a new use for compounds that inhibit phosphodiesterase 1 (PDE1), e.g., that inhibit PDE1-mediated suppression of the dopamine D1 receptor and/or progesterone signaling pathways, including, e.g., methods of treatment or prophylaxis for conditions which may be ameliorated by enhancing the progesterone signaling response, particularly female sexual dysfunction. | 2010-12-23 |
20100323998 | TOPICAL COMPOSITION CONTAINING THE COMBINATION OF MUPIROCIN AND BECLOMETHASONE - The present invention relates to a topical pharmaceutical composition comprising mupirocin and beclomethasone, a process for its preparation, its use in the treatment of infected dermatoses caused by bacteria susceptible to mupirocin and in the treatment of secondary bacterial infections in patients of steroid responsive dermatoses. | 2010-12-23 |